HEADER HYDROLASE/HYDROLASE INHIBITOR 30-NOV-01 1KHP TITLE MONOCLINIC FORM OF PAPAIN/ZLFG-DAM COVALENT COMPLEX COMPND MOL_ID: 1; COMPND 2 MOLECULE: PAPAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PAPAIN, RESIDUES 134-345; COMPND 5 SYNONYM: PAPAYA PROTEINASE I, PPI; COMPND 6 EC: 3.4.22.2; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: PEPTIDIC INHIBITOR; COMPND 9 CHAIN: I; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CARICA PAPAYA; SOURCE 3 ORGANISM_COMMON: PAPAYA; SOURCE 4 ORGANISM_TAXID: 3649; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES KEYWDS PROTEASE INHIBITOR, DIAZOMETHYLKETONE INHIBITOR, IRREVERSIBLE KEYWDS 2 INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.JANOWSKI,M.KOZAK,E.JANKOWSKA,Z.GRZONKA,M.JASKOLSKI REVDAT 6 16-AUG-23 1KHP 1 LINK REVDAT 5 13-JUL-11 1KHP 1 VERSN REVDAT 4 24-FEB-09 1KHP 1 VERSN REVDAT 3 15-MAR-05 1KHP 1 JRNL REVDAT 2 03-FEB-04 1KHP 1 REMARK REVDAT 1 09-SEP-03 1KHP 0 JRNL AUTH R.JANOWSKI,M.KOZAK,E.JANKOWSKA,Z.GRZONKA,M.JASKOLSKI JRNL TITL TWO POLYMORPHS OF A COVALENT COMPLEX BETWEEN PAPAIN AND A JRNL TITL 2 DIAZOMETHYLKETONE INHIBITOR JRNL REF J.PEPT.RES. V. 64 141 2004 JRNL REFN ISSN 1397-002X JRNL PMID 15357669 JRNL DOI 10.1111/J.1399-3011.2004.00181.X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.KOZAK,E.KOZIAN,Z.GRZONKA,M.JASKOLSKI REMARK 1 TITL CRYSTALLIZATION AND PRELIMINARY CRYSTALLOGRAPHIC STUDIES OF REMARK 1 TITL 2 A NEW CRYSTAL FORM OF PAPAIN FROM CARICA PAPAYA. REMARK 1 REF ACTA BIOCHIM.POL. V. 44 601 1997 REMARK 1 REFN ISSN 0001-527X REMARK 1 REFERENCE 2 REMARK 1 AUTH Z.GRZONKA,E.JANKOWSKA,E.WIECZERZAK,F.KASPRZYKOWSKI, REMARK 1 AUTH 2 L.LANKIEWICZ,W.WICZK,P.DRABIK,J.CIARKOWSKI,R.JANOWSKI, REMARK 1 AUTH 3 M.KOZAK,M.JASKOLSKI,A.GRUBB REMARK 1 TITL STRUCTURAL STUDIES OF CYSTEINE PROTEASES AND THEIR REMARK 1 TITL 2 INHIBITORS REMARK 1 REF ACTA BIOCHIM.POL. V. 48 1 2001 REMARK 1 REFN ISSN 0001-527X REMARK 1 REFERENCE 3 REMARK 1 AUTH J.DRENTH,K.H.KALK,H.M.SWEN REMARK 1 TITL BINDING OF CHLOROMETHYL KETONE SUBSTRATE ANALOGUES TO REMARK 1 TITL 2 CRYSTALLINE PAPAIN. REMARK 1 REF BIOCHEMISTRY V. 15 3731 1976 REMARK 1 REFN ISSN 0006-2960 REMARK 1 REFERENCE 4 REMARK 1 AUTH R.W.PICKERSGILL,G.W.HARRIS,E.GARMAN REMARK 1 TITL STRUCTURE OF MONOCLINIC PAPAIN AT 1.60 ANGSTROMS RESOLUTION. REMARK 1 REF ACTA CRYSTALLOGR.,SECT.B V. 48 59 1992 REMARK 1 REFN ISSN 0108-7681 REMARK 1 DOI 10.1107/S0108768191006572 REMARK 1 REFERENCE 5 REMARK 1 AUTH C.CZAPLEWSKI,Z.GRZONKA,M.JASKOLSKI,F.KASPRZYKOWSKI,M.KOZAK, REMARK 1 AUTH 2 E.POLITOWSKA,J.CIARKOWSKI REMARK 1 TITL BINDING MODES OF A NEW EPOXYSUCCINYL-PEPTIDE INHIBITOR OF REMARK 1 TITL 2 CYSTEINE PROTEASES. WHERE AND HOW DO CYSTEINE PROTEASES REMARK 1 TITL 3 EXPRESS THEIR SELECTIVITY? REMARK 1 REF BIOCHIM.BIOPHYS.ACTA V.1431 290 1999 REMARK 1 REFN ISSN 0006-3002 REMARK 1 DOI 10.1016/S0167-4838(99)00053-9 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 88.8 REMARK 3 NUMBER OF REFLECTIONS : 10783 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.185 REMARK 3 R VALUE (WORKING SET) : 0.180 REMARK 3 FREE R VALUE : 0.229 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1165 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1679 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 53 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 26.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 22.10 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.22000 REMARK 3 B22 (A**2) : 0.57000 REMARK 3 B33 (A**2) : 0.74000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.12000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.261 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.198 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.168 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 6.196 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : 0.016 ; 0.021 REMARK 3 ANGLE DISTANCE (A) : 0.025 ; 0.030 REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : 0.007 ; 0.020 REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : 0.108 ; 0.200 REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 0.793 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.300 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.451 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.784 ; 4.500 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: MAXIMUM LIKELIHOOD ALGORITHM. TLS REMARK 3 PARAMETERS WERE USED. THE PHQ (CARBOBENZOXY- OR REMARK 3 BENZYLOXYCARBONYL-) BLOCKING GROUP AT THE N-TERMINUS OF THE REMARK 3 INHIBITOR IS NOT VISIBLE IN ELECTRON DENSITY DUE TO DISORDER AND REMARK 3 WAS NOT INCLUDED IN THE MODEL. REMARK 4 REMARK 4 1KHP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 10-DEC-01. REMARK 100 THE DEPOSITION ID IS D_1000014973. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-MAR-98 REMARK 200 TEMPERATURE (KELVIN) : 293 REMARK 200 PH : 9.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : MACSCIENCE REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 12041 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 88.9 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : 0.12300 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 75.1 REMARK 200 DATA REDUNDANCY IN SHELL : 1.74 REMARK 200 R MERGE FOR SHELL (I) : 0.32800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1PPN REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.12 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 68% METHANOL/ETHANOL (2:1), 34 MM REMARK 280 NACL, 50 MM 2-AMINOETHANOL/HCL, PH 9.2, VAPOR DIFFUSION, HANGING REMARK 280 DROP, TEMPERATURE 292K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 24.46500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 790 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9530 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -6.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, I REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE PEPTIDIC INHIBITOR IS COVALENTLY LINKED TO THE SG ATOM OF CYS REMARK 400 25 OF THE PROTEIN VIA A METHYLKETONE GROUP. THE NON-STANDARD REMARK 400 TRIPEPTIDE IS N-TERMINALLY PROTECTED BY THE BENZYLOXYCARBONYL-GROUP REMARK 400 PHQ WHICH IS NOT VISIBLE IN ELECTRON DENSITY REMARK 400 REMARK 400 THE L-LEUCYL-N-(2-OXOPROPYL)-L-PHENYLALANINAMIDE IS PEPTIDE-LIKE, A REMARK 400 MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: L-LEUCYL-N-(2-OXOPROPYL)-L-PHENYLALANINAMIDE REMARK 400 CHAIN: I REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PHQ I 250 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 108 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 93 -140.40 -125.58 REMARK 500 GLN A 128 161.48 177.87 REMARK 500 ASP A 158 15.87 -157.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 CYS A 25 -14.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 THE PEPTIDIC INHIBITOR IS COVALENTLY LINKED TO THE SG ATOM OF CYS REMARK 600 25 OF THE PROTEIN VIA A METHYLKETONE GROUP. THE NON-STANDARD REMARK 600 TRIPEPTIDE IS N-TERMINALLY PROTECTED BY THE BENZYLOXYCARBONYL-GROUP REMARK 600 PHQ WHICH IS NOT VISIBLE IN ELECTRON DENSITY REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN I OF PEPTIDIC INHIBITOR REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PAD RELATED DB: PDB REMARK 900 PAPAIN-ACETYL-ALANYL-ALANYL-PHENYLALANYL-METHYLENYLALANYL REMARK 900 DERIVATIVE (/ACAAPACK) REMARK 900 RELATED ID: 5PAD RELATED DB: PDB REMARK 900 PAPAIN-BENZYLOXYCARBONYL-GLYCYL-PHENYLALANYL-METHYLENYLGLYCYL REMARK 900 DERIVATIVE (/ZGPGCK) REMARK 900 RELATED ID: 6PAD RELATED DB: PDB REMARK 900 PAPAIN-BENZYLOXYCARBONYL-PHENYLALANYL-METHYLENYLALANYL DERIVATIVE (/ REMARK 900 ZPACK) REMARK 900 RELATED ID: 9PAP RELATED DB: PDB REMARK 900 PAPAIN CYS 25 OXIDIZED REMARK 900 RELATED ID: 1PPN RELATED DB: PDB REMARK 900 PAPAIN CYS 25 WITH BOUND ATOM REMARK 900 RELATED ID: 2PAD RELATED DB: PDB REMARK 900 PAPAIN-CYSTEINYL DERIVATIVE OF CYS 25 (/PAPSSCYS) REMARK 900 RELATED ID: 1PE6 RELATED DB: PDB REMARK 900 PAPAIN COMPLEX WITH E-64-C REMARK 900 RELATED ID: 1PIP RELATED DB: PDB REMARK 900 PAPAIN COMPLEX WITH SUCCINYL-GLN-VAL-VAL-ALA-ALA-P-NITROANILIDE REMARK 900 RELATED ID: 1PPP RELATED DB: PDB REMARK 900 PAPAIN COMPLEX WITH E64-C (FORM II) REMARK 900 RELATED ID: 1PPD RELATED DB: PDB REMARK 900 2-HYDROXYETHYLTHIOPAPAIN - CRYSTAL FORM D REMARK 900 RELATED ID: 1POP RELATED DB: PDB REMARK 900 PAPAIN COMPLEX WITH LEUPEPTIN (N-ACETYL-L-LEUCYL-L-LEUCYL-L- REMARK 900 ARGININAL) REMARK 900 RELATED ID: 1STF RELATED DB: PDB REMARK 900 PAPAIN (CYS 25 CARBOXYMETHYLATED) COMPLEXED WITH THE INHIBITOR REMARK 900 STEFIN B (CYSTATIN B) MUTANT WITH CYS I 8 REPLACED BY SER (C(I 8)S) REMARK 900 RELATED ID: 1CVZ RELATED DB: PDB REMARK 900 PAPAIN WITH CLIK148 (CATHEPSIN L SPECIFIC INHIBITOR) REMARK 900 RELATED ID: 1KHQ RELATED DB: PDB REMARK 900 ORTHORHOMBIC FORM OF PAPAIN/ZLFG-DAM COVALENT COMPLEX DBREF 1KHP A 1 212 UNP P00784 PAPA_CARPA 134 345 DBREF 1KHP I 250 254 PDB 1KHP 1KHP 250 254 SEQRES 1 A 212 ILE PRO GLU TYR VAL ASP TRP ARG GLN LYS GLY ALA VAL SEQRES 2 A 212 THR PRO VAL LYS ASN GLN GLY SER CYS GLY SER CYS TRP SEQRES 3 A 212 ALA PHE SER ALA VAL VAL THR ILE GLU GLY ILE ILE LYS SEQRES 4 A 212 ILE ARG THR GLY ASN LEU ASN GLU TYR SER GLU GLN GLU SEQRES 5 A 212 LEU LEU ASP CYS ASP ARG ARG SER TYR GLY CYS ASN GLY SEQRES 6 A 212 GLY TYR PRO TRP SER ALA LEU GLN LEU VAL ALA GLN TYR SEQRES 7 A 212 GLY ILE HIS TYR ARG ASN THR TYR PRO TYR GLU GLY VAL SEQRES 8 A 212 GLN ARG TYR CYS ARG SER ARG GLU LYS GLY PRO TYR ALA SEQRES 9 A 212 ALA LYS THR ASP GLY VAL ARG GLN VAL GLN PRO TYR ASN SEQRES 10 A 212 GLU GLY ALA LEU LEU TYR SER ILE ALA ASN GLN PRO VAL SEQRES 11 A 212 SER VAL VAL LEU GLU ALA ALA GLY LYS ASP PHE GLN LEU SEQRES 12 A 212 TYR ARG GLY GLY ILE PHE VAL GLY PRO CYS GLY ASN LYS SEQRES 13 A 212 VAL ASP HIS ALA VAL ALA ALA VAL GLY TYR GLY PRO ASN SEQRES 14 A 212 TYR ILE LEU ILE LYS ASN SER TRP GLY THR GLY TRP GLY SEQRES 15 A 212 GLU ASN GLY TYR ILE ARG ILE LYS ARG GLY THR GLY ASN SEQRES 16 A 212 SER TYR GLY VAL CYS GLY LEU TYR THR SER SER PHE TYR SEQRES 17 A 212 PRO VAL LYS ASN SEQRES 1 I 5 PHQ LEU PHE GLY 0HQ HET 0HQ I 254 1 HETNAM 0HQ DIAZOMETHANE HETSYN 0HQ DIAZOMETHYL GROUP FORMUL 2 0HQ C H2 N2 FORMUL 3 HOH *53(H2 O) HELIX 1 1 SER A 24 GLY A 43 1 20 HELIX 2 2 SER A 49 ASP A 57 1 9 HELIX 3 3 TYR A 61 GLY A 65 5 5 HELIX 4 4 TYR A 67 TYR A 78 1 12 HELIX 5 5 ARG A 96 GLY A 101 5 6 HELIX 6 6 ASN A 117 GLN A 128 1 12 HELIX 7 7 GLY A 138 TYR A 144 1 7 HELIX 8 8 GLY A 198 LEU A 202 5 5 SHEET 1 A 3 VAL A 130 LEU A 134 0 SHEET 2 A 3 HIS A 159 TYR A 166 -1 O ALA A 163 N VAL A 130 SHEET 3 A 3 VAL A 5 ASP A 6 -1 N VAL A 5 O TYR A 166 SHEET 1 B 5 VAL A 130 LEU A 134 0 SHEET 2 B 5 HIS A 159 TYR A 166 -1 O ALA A 163 N VAL A 130 SHEET 3 B 5 TYR A 170 LYS A 174 -1 O LYS A 174 N ALA A 162 SHEET 4 B 5 TYR A 186 LYS A 190 -1 O ILE A 187 N ILE A 173 SHEET 5 B 5 ILE A 148 PHE A 149 1 N PHE A 149 O ARG A 188 SHEET 1 C 2 GLY A 109 GLN A 112 0 SHEET 2 C 2 PHE A 207 VAL A 210 -1 O TYR A 208 N ARG A 111 SSBOND 1 CYS A 22 CYS A 63 1555 1555 2.04 SSBOND 2 CYS A 56 CYS A 95 1555 1555 2.01 SSBOND 3 CYS A 153 CYS A 200 1555 1555 2.02 LINK SG CYS A 25 C1 0HQ I 254 1555 1555 1.76 LINK C GLY I 253 C1 0HQ I 254 1555 1555 1.52 CISPEP 1 GLY A 151 PRO A 152 0 0.89 SITE 1 AC1 13 GLN A 19 GLY A 23 SER A 24 CYS A 25 SITE 2 AC1 13 TRP A 26 TYR A 61 GLY A 65 GLY A 66 SITE 3 AC1 13 TYR A 67 VAL A 133 ASP A 158 HIS A 159 SITE 4 AC1 13 HOH I 349 CRYST1 42.440 48.930 52.690 90.00 112.42 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023562 0.000000 0.009720 0.00000 SCALE2 0.000000 0.020439 0.000000 0.00000 SCALE3 0.000000 0.000000 0.020528 0.00000